宣武医院团队发现血管生成素2（ANGPT2）促进散发脑动静脉畸形进展,血管,畸形,生成素,病灶,周细胞,脑血管 ...

首都医科大学宣武医院神经外科洪韬、张鸿祺教授团队，在血管机制研究知名期刊《Angiogenesis》杂志上发表了题为 “Inhibition of Angiopoietin‑2 rescues sporadic brain arteriovenous ...

北京宣武医院的研究团队近日在国际知名期刊《Angiogenesis》上发表了一项重要研究，揭示了血管生成素2（ANGPT2）在促进散发性脑动静脉畸形（BAVM）进展方面的重要作用。此种先天性神经血管疾病是导致青少年出血性卒中的一大元凶，现有的外科治疗方法往往会损伤周围正常脑组织，从而使临床需求愈加迫切。

Pfizer received accelerated approval from the FDA for its Braftovi combo regimen to treat treatment-naïve patients with BRAFV600E-mutant mCRC. The approval was based on a clinically meaningful ...

Chemoradiotherapy (CRT) followed by sequential tislelizumab (TIS) + CAPOX and TIS monotherapy for organ preservation in locally advanced low rectal cancer. A phase 2, multicenter, open-label study of ...

Cetuximab and vemurafenib plus liposomal irinotecan (II), leucovorin and fluorouracil for BRAFV600E-mutated advanced colorectal cancer (IMPROVEMENT2): A multicenter, open-label, randomized controlled ...

Langerhans cell histiocytosis (LCH) is a disease caused by clonal expansion of CD1a+/CD207+ cells and is characterized by organ involvement and dysfunction. Treatment of LCH in children is ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI ® (encorafenib) in combination with cetuximab (marketed as ...